Abstract:Objective: Endoplasmic reticulum (ER) stress has therapeutic potential for a variety of malignancies, including glioma. In this study, bioinformatics was used to analyze ER stress-related genes (ERGs) in glioblastoma (GBM), explore their functions and pathways, construct prognostic models, and explore new treatment strategies. Methods: Various bioinformatics algorithms were utilized to screen for ERGs and construct a risk model. According to the expression of ERGs, different subtypes were classified using the consensus clustering method. Gene Set Variation Analysis (GSVA) and Gene Set Enrichment Analysis (GSEA) were performed on the subtypes. Based on screened risk genes, GBM patients were divided into Train and Test groups in a 1:1 ratio. The prognostic model was validated through Receiver Operating Characteristic (ROC) curve analysis and independent prognostic analysis. The model was further validated by comparing the risk scores between high-risk and low-risk groups, and comparisons were made in terms of survival time, immune microenvironment, and pathway regulation. Drug sensitivity was used to screen drugs for low- and high- risk group, and single-cell RNA sequencing (scRNA-seq) analysis were utilized to explore the expression distribution of risk genes in GBM. Results: According to the ERGs, GBM samples can be divided into two groups with significant differences. Cluster A showed better survival rates compared to Cluster B. GSVA and GSEA analysis revealed that Cluster A was mainly enriched in glutamate receptor signaling pathway, synaptic transmission between neurons, postsynaptic density membrane, postsynaptic membrane, and synaptic vesicle membrane functions. It is worth noting that 8 ERGs were screened as model genes, which can effectively and independently predicate the survival risk of GBM patients with high accuracy and discrimination ability. Subsequently, changes in immune cell populations were observed in high-risk and low-risk groups, with differences in memory B cells and resting CD4 memory T cells between the high-risk and low-risk groups. The high-risk group had higher levels of memory B cells, while the low-risk group had higher levels of resting CD4 memory T cells. Furthermore, potential therapeutic strategies were identified, with BI-2536, Daporinad, SB505124, UMI-77, and Vorinostat identified for the low-risk group, while AZD8055, Camptothecin, Gemcitabine, PD0325901, and Topotecan identified for the high-risk group. scRNA-seq identified Ribosomal Protein L10 (RPL10) as one of the eight ER stress-related genes, primarily expressed in malignant cells of various tumors. Conclusion: This study identified eight ERGs and constructed a risk model based on bioinformatics analysis, which can be used for prognosis prediction and drug screening.

Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide

Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma

Knockdown of NF-E2-related Factor 2 Inhibits the Proliferation and Growth of U251MG Human Glioma Cells in a Mouse Xenograft Model

P01.23 * NEUROTENSIN PROMOTES THE PROGRESSION OF MALIGNANT GLIOMA THROUGH NTSR1 AND IMPACTS THE PROGNOSIS OF GLIOMA PATIENTS

Tmic-18. Role Of Neurotransmitters In Glioblastoma Pathophysiology: Emerging Insights

CCNA2 and NEK2 regulate glioblastoma progression by targeting the cell cycle

Experimental Studies on Correlation Between Nucleolus Spindle-Related Protein 1 and the Malignant Progression and Prognosis of Human Glioblastoma Multiforme

Expression of NANOG in Human Gliomas and Its Relationship with Undifferentiated Glioma Cells

Tmic-82. Characterization Of Genetic Markers And Biological Processes Underlying The Transition Of Glioblastoma Cells From A Differentiated To A Stem-Cell-Like State

Overexpression of NNMT in Glioma Aggravates Tumor Cell Progression: an Emerging Therapeutic Target.

Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas

NQO1 Drives Glioblastoma Cell Aggressiveness Through EMT Induction Via the PI3K/Akt/mTOR/Snail Pathway

Increased Neuromedin B is Associated with a Favorable Prognosis in Glioblastoma

CNSC-12. NEURONAL DIFFERENTIATION DRIVES THE ANTI-TUMOR EFFICACY OF MEK INHIBITION IN GLIOBLASTOMA

Combined bulk RNA-seq and single-cell RNA-seq identifies a necroptosis-related prognostic signature associated with inhibitory immune microenvironment in glioma

Endoplasmic reticulum stress-related gene expression patterns in glioblastoma models identified by single-cell RNA sequencing: Implications for prognosis and treatment

Abstract 4392: Neuropeptide Y system in glioblastoma

Neurotensin Promotes the Progression of Malignant Glioma Through Ntsr1 and Impacts the Prognosis of Glioma Patients

Knockdown of NUSAP1 Inhibits Cell Proliferation and Invasion Through Down-Regulation of TOP2A in Human Glioblastoma

Novel Biomarker Genes for Prognosis of Survival and Treatment of Glioma

Candidate genes influencing sensitivity and resistance of human glioblastoma to Semustine